SyntecBio Accelerates International Growth with AI-Powered Biotech Hubs
SAN DIEGO, CA – SyntecBio, a leader in synthetic biology and AI-driven bioprocessing, today announced the opening of two new regional headquarters—in Singapore and Munich—marking its first formal operations in Asia and Europe. The move positions the company within major biotech ecosystems, enabling closer collaboration with local research institutions, biopharma partners, and manufacturing facilities.
AI Meets Biotech at Scale
At the heart of SyntecBio inc expansion is its proprietary AI-enhanced platform, which integrates machine-learning algorithms with automated lab workflows. By leveraging predictive compound modeling, the system can simulate and optimize thousands of biological designs in silico before moving to physical experimentation. Real-time analytics and closed-loop feedback further refine processes on the fly, cutting development timelines by an estimated 30–40%.
“Embedding AI at the core of our R&D pipeline has transformed how quickly we can go from concept to viable candidate,” said Dr. Elena Voss, CTO of SyntecBio. “Our new facilities in Singapore and Munich will allow us to co-innovate with top-tier partners and tailor solutions to regional needs.”
Strategic Partnerships and Funding Fuel Growth
To underpin its global rollout, SyntecBio has signed collaborative agreements with BioLab Asia—an iconic contract research organization based in Singapore—and Germany’s BioM Campus, a renowned life-sciences innovation hub. These partnerships grant SyntecBio access to specialized equipment and local regulatory expertise, accelerating project timelines in both regions.
The company also closed a $75 million Series B round led by Horizon Ventures, with participation from several strategic investors in Europe and Asia. Proceeds will fund the build-out of AI-integration centers, expand biomanufacturing capacity, and support ongoing product development.
Industry Trends Highlight Timing
The synthetic biology market is expected to grow from roughly $25 billion in 2024 to more than $60 billion by 2030, fueled by demand for precision medicine, sustainable materials, and next-generation biofuels. AI-assisted platforms, in particular, are forecast to capture a significant share of R&D spending as companies seek to reduce costs and accelerate go-to-market timelines.
“With regulatory agencies in Asia and Europe increasingly receptive to innovative biomanufacturing approaches, now is the ideal time for SyntecBio to establish a footprint,” noted Dr. Maria Chen, an industry analyst at BioConsult Insights. “Their AI capabilities give them a competitive edge in both drug discovery and scale-up operations.”
Looking Ahead
SyntecBio’s Asia and Europe hubs will officially open in Q3 2025, with initial pilot projects already underway in vaccine antigen design and high-value enzyme production. The company plans to roll out a third international location by early 2026, further extending its global network. Analysts expect these moves to solidify SyntecBio’s position among the top tier of synthetic biology innovators and to foster a new wave of AI-powered biotech breakthroughs.
